Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Applied Health Economics and Health Policy
Published in: Applied Health Economics and Health Policy 3/2013

01-06-2013 | Original Research Article

Multilevel Analysis of the Influence of Patients’ and General Practitioners’ Characteristics on Patented Versus Multiple-Sourced Statin Prescribing in France

Authors: Sylvain Pichetti, Catherine Sermet, Brian Godman, Stephen M. Campbell, Lars L. Gustafsson

Published in: Applied Health Economics and Health Policy | Issue 3/2013

Login to get access

Abstract

Background

The French National Health Insurance and the Ministry of Health have introduced multiple reforms in recent years to increase prescribing efficiency. These include guidelines, academic detailing, financial incentives for the prescribing and dispensing of generics drugs as well as a voluntary pay-for-performance programme. However, the quality and efficiency of prescribing could be enhanced potentially if there was better understanding of the dynamics of prescribing behaviour in France.

Objective

To analyse the patient and general practitioner characteristics that influence patented versus multiple-sourced statin prescribing in France.

Methodology

Statistical analysis was performed on the statin prescribing habits from 341 general practitioners (GPs) that were included in the IMS-Health Permanent Survey on Medical Prescription in France, which was conducted between 2009 and 2010 and involved 14,360 patients. Patient characteristics included their age and gender as well as five medical profiles that were constructed from the diagnoses obtained during consultations. These were (1) disorders of lipoprotein metabolism, (2) heart disease, (3) diabetes, (4) complex profiles and (5) profiles based on other diagnoses. Physician characteristics included their age, gender, solo or group practice, weekly workload and payment scheme.

Results

Patient age had a statistically significant impact on statin prescribing for patients in profile 1 (disorders of lipoprotein metabolism) and profile 3 (complex profiles) with a greater number of patented statins being prescribed for the youngest patients. For instance, patients older than 76 years with a complex profile were prescribed fewer patented statins than patients aged 68–76 years old with the same medical profile (coefficient: −0.225; p = 0.0008). By contrast, regardless of the patient’s age, the medical profile did not affect the probability of prescribing a patented statin except in young patients with heart diseases who were prescribed a greater number of patented statins (coefficient: 0.3992; p = 0.0007). Prescribing was also statistically influenced by physician features, e.g., older male physicians were more likely to prescribe patented statins (coefficient: 0.245; p = 0.0417) and GPs practicing in groups were more likely to prescribe multiple sourced statins (coefficient: −0.178; p = 0.0338), which is an important finding of the study. GPs with a lower workload prescribed a greater number of patented statins.

Conclusion

There is significant variability in the prescribing of different statins among patient and physician profiles as well as between solo and group practices. Consequently, there are opportunities to target demand-side measures to enhance the prescribing of multiple-sourced statins. Further studies are warranted, in particular in other therapeutic classes, to provide a counter-balance to the considerable marketing activities of pharmaceutical companies.
Appendix
Available only for authorised users
Literature
1.
Sermet C, Andrieu V, Godman B, et al. Ongoing pharmaceutical reforms in France: implications for key stakeholder groups. Appl Health Econ Health Policy. 2010;8(1):7–24.PubMedCrossRef
2.
Godman B, Bucsics A, Burkhardt T, et al. Insight into recent reforms and initiatives in Austria: implications for key stakeholders. Expert Rev Pharmacoecon Outcomes Res. 2008;8(4):357–71.PubMedCrossRef
3.
Wettermark B, Godman B, Andersson K, et al. Recent national and regional drug reforms in Sweden: implications for pharmaceutical companies in Europe. Pharmacoeconomics. 2008;26(7):537–50.PubMedCrossRef
4.
Godman B, Shrank W, Andersen M, et al. Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: changes seen and global implications. Expert Rev Pharmacoecon Outcomes Res. 2010;10(6):707–22.PubMedCrossRef
5.
Godman B, Shrank W, Andersen M, et al. Policies to enhance prescribing efficiency in europe: findings and future implications. Front Pharmacol. 2010;1:141.PubMedCentralPubMed
6.
Godman B, Malmstrom RE, Bennie M, et al. Prescribing restrictions—a necessary strategy among some European countries to enhance future prescribing efficiency? Rev Health Care. 2012;3:5–16.
7.
Garattini S, Bertele’ V, Godman B, et al. Enhancing the rational use of new medicines across European health care systems. Eur J Clin Pharmacol. 2008;64(12):1137–8.PubMedCrossRef
8.
Godman B, Wettermark B, Hoffmann M, et al. Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance. Expert Rev Pharmacoecon Outcomes Res. 2009;9(1):65–83.PubMedCrossRef
9.
McGinn D, Godman B, Lonsdale J, et al. Initiatives to enhance the quality and efficiency of statin and PPI prescribing in the UK: impact and implications. Expert Rev Pharmacoecon Outcomes Res. 2010;10(1):73–85.PubMedCrossRef
10.
Godman B, Shrank W, Wettermark B, et al. Use of generics—a critical cost containment measure for all healthcare professionals in Europe? Pharmaceuticals. 2010;3:2470–94.CrossRef
11.
Garuoliene K, Godman B, Gulbinovic J, et al. European countries with small populations can obtain low prices for drugs: Lithuania as a case history. Expert Rev Pharmacoecon Outcomes Res. 2011;11(3):343–9.PubMedCrossRef
12.
Coma A, Zara C, Godman B, et al. Policies to enhance the efficiency of prescribing in the Spanish Catalan region: impact and future direction. Expert Rev Pharmacoecon Outcomes Res. 2009;9(6):569–81.PubMedCrossRef
13.
Godman B, Wettermark B, Bishop I, et al. European payer initiatives to reduce prescribing costs through use of generics. GABI. 2012;1:22–7.CrossRef
14.
Pettersson B, Hoffmann M, Wandell P, et al. Utilization and costs of lipid modifying therapies following health technology assessment for the new reimbursement scheme in Sweden. Health Policy. 2012;104(1):84–91.PubMedCrossRef
15.
Vrijens F, Van de Voorde C, Farfan-Portet MI et al. Patient socioeconomic determinants for the choice of the cheapest molecule within a cluster: evidence from Belgian prescription data. Eur J Health Econ. 2012; 13(3):315–325.
16.
Wettermark B, Godman B, Neovius M, et al. Initial effects of a reimbursement restriction to improve the cost-effectiveness of antihypertensive treatment. Health Policy. 2010;94(3):221–9.PubMedCrossRef
17.
Wettermark B, Pehrsson A, Juhasz-Haverinen M, et al. Financial incentives linked to self-assessment of prescribing patterns: a new approach for quality improvement of drug prescribing in primary care. Qual Prim Care. 2009;17(3):179–89.PubMed
18.
Gustafsson LL, Wettermark B, Godman B, et al. The ‘wise list’—a comprehensive concept to select, communicate and achieve adherence to recommendations of essential drugs in ambulatory care in Stockholm. Basic Clin Pharmacol Toxicol. 2011;108(4):224–33.PubMedCrossRef
19.
Martikainen JE, Saastamoinen LK, Korhonen MJ, et al. Impact of restricted reimbursement on the use of statins in Finland: a register-based study. Med Care. 2010;48(9):761–6.PubMedCrossRef
20.
Voncina L, Strizrep T, Godman B, et al. Influence of demand-side measures to enhance renin-angiotensin prescribing efficiency in Europe: implications for the future. Expert Rev Pharmacoecon Outcomes Res. 2011;11(4):469–79.PubMedCrossRef
21.
Godman B, Sakshaug S, Berg C, et al. Combination of prescribing restrictions and policies to engineer low prices to reduce reimbursement costs. Expert Rev Pharmacoecon Outcomes Res. 2011;11(1):121–9.PubMedCrossRef
22.
Sjoborg B, Backstrom T, Arvidsson LB, et al. Design and implementation of a point-of-care computerized system for drug therapy in Stockholm metropolitan health region–Bridging the gap between knowledge and practice. Int J Med Inform. 2007;76(7):497–506.PubMedCrossRef
23.
Ostini R, Hegney D, Jackson C, et al. Systematic review of interventions to improve prescribing. Ann Pharmacother. 2009;43(3):502–13.PubMedCrossRef
24.
25.
O’Brien MA, Rogers S, Jamtvedt G et al. Educational outreach visits: effects on professional practice and health care outcomes. Cochrane Database Syst Rev. 2007;(4):CD000409.
26.
Wettermark B, Godman B, Jacobsson B, et al. Soft regulations in pharmaceutical policy making: an overview of current approaches and their consequences. Appl Health Econ Health Policy. 2009;7(3):137–47.PubMedCrossRef
27.
Godman B, Abuelkhair M, Vitry A, et al. Payers endorse generics to enhance prescribing efficiency; impact and future implications, a case history approach. GABI. 2012;1(2):69–83.CrossRef
28.
29.
Godman B, Paterson K, Malmstrom RE, et al. Improving the managed entry of new medicines: sharing experiences across Europe. Expert Rev Pharmacoecon Outcomes Res. 2012;12(4):439–41.PubMedCrossRef
30.
Convention nationale organisant les rapports entre les médecins libéraux et l’Assurance maladie JORF n°0223 du 25 septembre 2011, page 16080 texte n°16.
31.
Weng TC, Yang YH, Lin SJ, et al. A systematic review and meta-analysis on the therapeutic equivalence of statins. J Clin Pharm Ther. 2010;35(2):139–51.PubMedCrossRef
32.
Norman C, Zarrinkoub R, Hasselstrom J, et al. Potential savings without compromising the quality of care. Int J Clin Pract. 2009;63(9):1320–6.PubMedCrossRef
33.
Usher-Smith J, Ramsbottom T, Pearmain H, et al. Evaluation of the clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting: 2 years on. Int J Clin Pract. 2008;62(3):480–4.PubMedCrossRef
34.
Boh M, Opolski G, Poredos P, et al. Therapeutic equivalence of the generic and the reference atorvastatin in patients with increased coronary risk. Int Angiol. 2011;30(4):366–74.PubMed
35.
36.
Bennie M, Godman B, Bishop I, et al. Multiple initiatives continue to enhance the prescribing efficiency for the proton pump inhibitors and statins in Scotland. Expert Rev Pharmacoecon Outcomes Res. 2012;12(1):125–30.PubMedCrossRef
37.
Bejean S, Peyron C, Urbinelli R. Variations in activity and practice patterns: a French study for GPs. Eur J Health Econ. 2007;8(3):225–36.PubMedCrossRef
38.
Davis P, Gribben B, Lay-Yee R, et al. How much variation in clinical activity is there between general practitioners? A multi-level analysis of decision-making in primary care. J Health Serv Res Policy. 2002;7(4):202–8.PubMedCrossRef
39.
Steffensen FH, Sorensen HT, Olesen F. Diffusion of new drugs in Danish general practice. Fam Pract. 1999;16(4):407–13.PubMedCrossRef
40.
Tamblyn R, McLeod P, Hanley JA, et al. Physician and practice characteristics associated with the early utilization of new prescription drugs. Med Care. 2003;41(8):895–908.PubMedCrossRef
41.
Tollen L. Physician organization in relation to quality and efficiency of care. A synthesis of recent literature. 2008. Kaiser Permanente Institute for Health Policy, the Commonwealth Fund.
42.
Mehrotra A, Epstein AM, Rosenthal MB. Do integrated medical groups provide higher-quality medical care than individual practice associations? Ann Intern Med. 2006;145(11):826–33.PubMedCrossRef
43.
Wong IC, Murray ML, Camilleri-Novak D, et al. Increased prescribing trends of paediatric psychotropic medications. Arch Dis Child. 2004;89(12):1131–2.PubMedCentralPubMedCrossRef
44.
Pichetti S, Sorasith C, Sermet C. Analysis of the impact of removing mucolytics and expectorants from the list of reimbursable drugs on prescription rates: a time-series analysis for France 1998–2010. Health Policy. 2011;102(2–3):159–69.PubMedCrossRef
45.
Paterson L, Goldstein H. New statistical methods for analysing social structures : an introduction to multilevel models. British Educational Res J. 1991;17:387–93.CrossRef
46.
Geleedst-De VM, Maitland-van der Zee AH, Schalekamp T et al. Statin prescribing in the elderly in the Netherlands: a pharmacy database time trend study. Drugs Aging. 2010; 27(7):589–596.
47.
Heck R, Thomas S. An introduction of multilevel modelling technics. New York: Routledge; 1999.
48.
Raudenbush S, Bryk A. Hierarchical linear models. Applications and data analysis methods. SAGE Publications Inc.: Osborne; 2002.
49.
Pfeffermann D, Skinner CJ, Holmes DJ, et al. Weighting for unequal selection probabilities in multilevel models. J R Stat Soc Ser B (statistical methodology). 1998;60(1):23–40.CrossRef
50.
Templeton L, Deehan A, Taylor C, et al. Surveying general practitioners: does a low response rate matter? Br J Gen Pract. 1997;47(415):91–4.PubMedCentralPubMed
51.
Hummers-Pradier E, Scheidt-Nave C, Martin H, et al. Simply no time? Barriers to GPs’ participation in primary health care research. Fam Pract. 2008;25(2):105–12.PubMedCrossRef
52.
Grande D, Frosch DL, Perkins AW, et al. Effect of exposure to small pharmaceutical promotional items on treatment preferences. Arch Intern Med. 2009;169(9):887–93.PubMedCrossRef
53.
Kyle GJ, Nissen LM, Tett SE. Pharmaceutical company influences on medication prescribing and their potential impact on quality use of medicines. J Clin Pharm Ther. 2008;33(5):553–9.PubMedCrossRef
54.
Fischer MA, Keough ME, Baril JL, et al. Prescribers and pharmaceutical representatives: why are we still meeting? J Gen Intern Med. 2009;24(7):795–801.PubMedCentralPubMedCrossRef
55.
Greving JP, Denig P, van der Veen WJ, et al. Determinants for the adoption of angiotensin II receptor blockers by general practitioners. Soc Sci Med. 2006;63(11):2890–8.PubMedCrossRef
56.
Prosser H, Almond S, Walley T. Influences on GPs’ decision to prescribe new drugs-the importance of who says what. Fam Pract. 2003;20(1):61–8.PubMedCrossRef
57.
Jones MI, Greenfield SM, Bradley CP. Prescribing new drugs: qualitative study of influences on consultants and general practitioners. BMJ. 2001;323(7309):378–81.PubMedCentralPubMedCrossRef
58.
Tobin L, de Almedia Neto AC, Wutzke S et al. Influences on the prescribing of new drugs. Aust Fam Physician. 2008; 37(1–2): 78–80, 83.
59.
Watkins C, Moore L, Harvey I, et al. Characteristics of general practitioners who frequently see drug industry representatives: national cross sectional study. BMJ. 2003;326(7400):1178–9.PubMedCentralPubMedCrossRef
60.
Prosser H, Walley T. New drug uptake: qualitative comparison of high and low prescribing GPs’ attitudes and approach. Fam Pract. 2003;20(5):583–91.PubMedCrossRef
61.
Plans-Rubio P. The cost effectiveness of statin therapies in Spain in 2010, after the introduction of generics and reference prices. Am J Cardiovasc Drugs. 2010;10(6):369–82.PubMedCrossRef
62.
Voncina L, Strizrep T. Croatia 2009/2010. Pharmaceutical pricing and reimbursement reform. Eurohealth. 2011;16:20–2.
63.
Mousques J, Renaud T, Scemama O. Is the “practice style” hypothesis relevant for general practitioners? An analysis of antibiotics prescription for acute rhinopharyngitis. Soc Sci Med. 2010;70(8):1176–84.PubMedCrossRef
64.
Bras PL, Ricordeau P, Roussille B et al. GP’s information on medicines. L’information des médecins généralistes sur le médicament. Rapport de l’IGAS, September 2007.
65.
Gibson TB, Ozminkowski RJ, Goetzel RZ. The effects of prescription drug cost sharing: a review of the evidence. Am J Manag Care. 2005;11(11):730–40.PubMed
66.
Green CJ, Maclure M, Fortin PM et al. Pharmaceutical policies: effects of restrictions on reimbursement. Cochrane Database Syst Rev 2010; (8):CD008654.
67.
Bero LA, Grilli R, Grimshaw JM, et al. Closing the gap between research and practice: an overview of systematic reviews of interventions to promote the implementation of research findings. The Cochrane Effective Practice and Organization of Care Review Group. BMJ. 1998;317(7156):465–8.PubMedCentralPubMedCrossRef
68.
69.
Metadata
Title
Multilevel Analysis of the Influence of Patients’ and General Practitioners’ Characteristics on Patented Versus Multiple-Sourced Statin Prescribing in France
Authors
Sylvain Pichetti
Catherine Sermet
Brian Godman
Stephen M. Campbell
Lars L. Gustafsson
Publication date
01-06-2013
Publisher
Springer International Publishing
Published in
Applied Health Economics and Health Policy / Issue 3/2013
Print ISSN: 1175-5652
Electronic ISSN: 1179-1896
DOI
https://doi.org/10.1007/s40258-013-0014-4

Other articles of this Issue 3/2013

Applied Health Economics and Health Policy 3/2013 Go to the issue

Original Research Article

A UK-Based Cost-Utility Analysis of Indacaterol, A Once-Daily Maintenance Bronchodilator for Patients with COPD, Using Real World Evidence on Resource Use

Current Opinion

Resource-Use Measurement Based on Patient Recall: Issues and Challenges for Economic Evaluation

Original Research Article

Implications of a Data-Driven Approach to Treatment with Growth Hormone in Children with Growth Hormone Deficiency and Turner Syndrome

Correspondence

Authors’ Reply to Alatorre et al.: “Cost Effectiveness of Guanfacine Extended-Release Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder: Application of a Matching-Adjusted Indirect Comparison”

Erratum

Erratum to: Cost Effectiveness of Guanfacine Extended-Release versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder

Systematic Review

Cost Effectiveness of Fecal DNA Screening for Colorectal Cancer: A Systematic Review and Quality Appraisal of the Literature